MapLight Therapeutics Inc. Raises $258.9 Million in US IPO Backed by Novo

We are tracking a noteworthy biotech move: the initial public offering of MapLight Therapeutics, Inc. (ticker “MPLT”), a clinical-stage firm targeting central nervous system (CNS) disorders. The focus keyword “MapLight Therapeutics Inc.” appears early, emphasizing the company in the spotlight. The firm has secured about $258.9 million by selling 14.75 million shares at $17.00 each, plus a private placement of 476,707 shares to affiliates of Goldman Sachs Group Inc. at the same price. This IPO comes amid a rebounding biotech market, and MapLight is backed by major investors, including Novo Holdings A/S (via its venture arm). The company aims for a valuation of roughly $704 million post-IPO.